Recent advances in the treatment of acute myeloid leukemia
Omar Abdel-Wahab and Ross L Levine*

Address: Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

* Corresponding author: Ross L Levine (leviner@mskcc.org)

F1000 Medicine Reports 2010, 2:55 (doi:10.3410/M2-55)

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.

The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/medicine/content/2/55

Abstract

Acute myeloid leukemia (AML) is a disorder with significant molecular and clinical heterogeneity. Although there have been clear advances in the identification of somatic genetic and epigenetic alterations present in the malignant cells of patients with AML, translating this knowledge into an integrated view with an impact on the clinical treatment of AML has been slower to evolve. Recent clinical advances in the treatment of AML include studies demonstrating the benefit of dose-intensive daunorubicin therapy in induction chemotherapy for patients of any age. We also review use of the DNA methyltransferase inhibitor azacitidine for treatment of AML in elderly patients as well as a study of global patterns of DNA methylation in patients with AML. Lastly, we review a recent assessment of the role of allogeneic hematopoietic stem cell transplantation in AML in first complete remission.

Introduction and context

Acute myeloid leukemia (AML) is the more common acute leukemia in adults. Genetic and functional studies have demonstrated that AML develops as a result of acquisition of genetic and epigenetic alterations that result in abnormal differentiation and unlimited self-renewal. Although patients with AML, with the exception of acute promyelocytic leukemia, are treated with similar therapies, it has long been recognized that there is significant biological, clinical, and genetic heterogeneity in AML. Recent genetic studies have continued to elucidate molecular alterations in AML with clinical and prognostic significance, and there is an ever-increasing list of somatic genetic abnormalities described in AML. In addition to mutations in MLL, Flt3, NPM1, CEBPa, K/N-Ras, KIT, and WT1, mutations in the putative epigenetic modifiers TET2 [1-4] and ASXL1 [2,5] as well as in the metabolic enzymes IDH1 and IDH2 [6,7] have been described in AML in the past year.

Although increasing knowledge of the genetic abnormalities present in AML has continued to improve our understanding of the biology of this disorder, an integrated view of the genetic and epigenetic abnormalities found in AML is greatly needed. Even more challenging will be translating such a comprehensive characterization into a clinically useful decision algorithm.

In this review, we summarize the findings from four recent clinical studies of treatment in AML. The first two studies focus on optimizing induction chemotherapy regimens in AML using anthracycline dose-intensification. The third study evaluates the role of the DNA methyltransferase inhibitor azacitidine in the treatment of elderly patients with AML and a low blast count. The final study is a discussion of a recent meta-analysis regarding the use of allogeneic hematopoietic stem cell transplantation (HSCT) in first remission of AML.

Recent advances

Optimizing induction chemotherapy in AML with anthracycline dose-intensification

The current standard of care for induction chemotherapy of AML is 3 days of an anthracycline and 7 days of...
cytarabine (100-200 mg/m² continuous intravenous) [8]. While attempts to increase response rate with the addition of agents such as thioguanine [9], etoposide [10], fludarabine [11], and topotecan [11] have failed, two studies published in the fall of 2009 demonstrated that intensification of the dose of daunorubicin improves outcome in de novo AML [12,13].

The first study by the Eastern Cooperative Oncology Group randomized previously untreated AML patients aged 17-60 years to standard dose (45 mg/m²) or high-dose (90mg/m²) daunorubicin in combination with 7 days of cytarabine (100 mg/m² continuous infusion) [12]. Patients in complete remission (CR) were then offered allogeneic HSCT or high-dose cytarabine, with or without gemtuzumab ozogamicin, followed by allogeneic HSCT. Treatment with high-dose daunorubicin resulted in improved CR rate (70.6% versus 57.3%, P < 0.001) and longer overall survival (OS; median, 23.7 versus 15.7 months).

As the results of this study were published, Löwenberg et al. [13] simultaneously reported the use of a similar daunorubicin dose-intensification induction regimen in elderly AML patients. In this study, newly diagnosed AML patients aged 60 years or older (median age 67) were randomly assigned to receive cytarabine (200 mg/m² continuous intravenous infusion) plus daunorubicin for 3 days at the conventional dose of 45 mg/m² or at the escalated dose of 90 mg/m². This treatment was then followed by a second cycle of cytarabine at a dose of 1000 mg/m² every 12 hours for 6 days. The elevated dose of daunorubicin led to an increased CR rate (64% versus 54%, P = 0.002) but did not affect OS in the study in general. However, there was a significant improvement in OS in patients aged 60-65 years who received the higher-dose of daunorubicin compared with the conventional dose.

Importantly, in both studies, treatment with high-dose daunorubicin did not result in significant differences in hematologic toxicity or adverse events. Moreover, treatment with high-dose daunorubicin did not prolong time to receive consolidation therapy. These studies suggest that there is a dose-response relationship between anthacycline therapy and AML, and that anthacycline dose-intensification results in improved responses without marked increases in attendant toxicity. Whether dose-intensified daunorubicin is associated with improved long-term survival remains to be seen given the short duration of follow-up for these studies, and more importantly, whether specific molecularly defined subtypes of AML specifically benefit from dose-intensified induction regimens.

Use of azacitidine as treatment in AML

Given that most patients with AML are aged 60 years or older and that treatment with intensive chemotherapy (such as the dose-intense daunorubicin plus cytarabine induction described above) is limited to 30-60% of elderly AML patients [14], there has been great interest in developing alternative therapeutic strategies for elderly AML patients. However, clinical trials with low-dose cytarabine [15], the farnesyl transferase inhibitor tipifarnib [16], and gemtuzumab ozogamicin [17] have demonstrated little or no improvement in overall survival in elderly patients with AML. Importantly, a recent phase III randomized trial of the DNA methyltransferase inhibitor azacitidine demonstrated an improvement in survival as a single agent in older AML patients with 20-30% bone marrow blasts compared with ‘conventional care regimens’ [18]. In this study, conventional care regimens were defined as best supportive care, low-dose cytarabine, or intensive chemotherapy. Most patients (86%) were considered unfit for intensive chemotherapy and azacitidine resulted in an overall survival of 24.5 months compared with 16.0 months for patients receiving conventional care regimens (P < 0.001). Moreover, azacitidine was associated with fewer days in hospital and higher two-year overall survival rates.

With further clinical study of epigenetic targeted therapies in AML, it will be important to correlate response to epigenetic therapies with genome-wide methylation data before and after treatment. The largest study of the genome-wide methylation status of AML genomes was recently published by Figueroa et al. [19]. In this study, genome-wide promoter DNA methylation profiling was performed using the HELP assay (HpaII tiny fragment enrichment by ligation-mediated PCR). In the first part of the study the authors found that the known cytogenetic subsets of AML (e.g., t(15;17), inv(16), t(11q23)) were associated with distinct global DNA methylation patterns. More interestingly, the authors then integrated DNA methylation array data with gene-expression profiling and identified unique subsets of AML. These specific subsets of AML did not align with kinase abnormalities described in AML (mutations in Flt3, N/K-Ras, CBL, KIT, JAK2), suggesting that methylation and gene-expression changes in AML may be influenced by alterations other than single activating kinase mutations. As the molecular characterization of the epigenetic machinery and landscape of AML improves, it will be interesting to correlate data from
genome-wide methylation patterns of AML with mutations in epigenetic modifiers and with response to epigenetic targeted therapy.

**Current state of allogeneic HSCT for AML in first remission**

The goal of therapy in the treatment of younger patients with AML is to achieve a cure. While ≥70% of patients with AML aged <60 years will achieve first CR (CR1), a substantial number of patients relapse during or after consolidation therapy [20]. Thus, treatment with allogeneic HSCT in young patients with AML in CR1 has been frequently studied, but until recently the use of allogeneic HSCT was not well-defined for all risk groups of AML. Less than 1 year ago, Koreth et al. [21] performed a meta-analysis of all published data on the use of allogeneic HSCT versus non-allogeneic HSCT options (autologous HSCT, consolidation chemotherapy, or both) for patients with AML aged <60 years in CR1. They used an intention-to-treat analysis based on donor availability to capture information from all patients with AML evaluated for up-front allogeneic HSCT with a donor search as part of a prospective trial. They found that allogeneic HSCT significantly improved relapse-free survival and OS for intermediate- and poor-risk AML (based on cytogenetic risk) but not in good-risk AML in CR1. Five-year OS was estimated at 45% and 20% for intermediate- and poor-risk AML, respectively, with non-allogeneic HSCT options. This is compared with OS rates of 52% and 31% for patients with intermediate- and poor-risk AML, respectively, who underwent allogeneic HSCT.

Previous studies have shown that mutational status is an important predictor of outcome and treatment response in AML, including response to allogeneic HSCT. The landmark study by Schlenk et al. [22] demonstrated the importance of correlating mutational status of normal karyotype AML patients with likelihood of attaining complete remission after chemotherapy and chance of benefiting from an allogeneic HSCT. In this study, the mutational status of NPM1, FLT3, CEBPa, MLL, and N-Ras were assessed in 872 adults aged <60 years with cytogenetically normal AML. In addition to revealing the mutational frequency of each of these genes in normal karyotype AML, the study more importantly demonstrated that the factors associated with CR in normal karyotype AML include the genotype of mutant NPM1 without FLT3 internal tandem duplication (ITD), the mutant CEBPA genotype, and younger age. Moreover, because 150 individuals in this study underwent HSCT from an HLA-matched related donor, the authors were able to identify that the benefit of the transplant was limited to the subgroup of patients with FLT3 ITD or the genotype consisting of wild-type NPM1 and CEBPA without FLT3 ITD.

**Implications for clinical practice**

The recent clinical studies reviewed here demonstrate the benefit of high-dose daunorubicin in induction therapy of AML for patients of any age eligible to receive intensive chemotherapy [12,13]. Following successful achievement of complete remission, recent detailed meta-analyses suggest that allogeneic HSCT is beneficial for any patient in cytogenetically defined intermediate- or poor-risk categories [21]. For elderly AML patients with <30% bone marrow blasts who are not eligible to receive intensive chemotherapy, treatment with azacitidine appears to improve OS compared with alternative treatments [18]. Given that many molecular alterations in AML have been demonstrated to influence response to clinical therapies [8,12], further efforts to integrate genome-wide molecular alterations with treatment response and outcome are needed and will inform future analyses of the cohorts described in these clinical trials. Characterization of primary AML samples by the use of high-throughput genetic, epigenetic, and RNA/microRNA expression techniques continues to improve, and it will be important to incorporate molecular analyses into existing and future clinical trials to delineate genetic and epigenetic predictors of response and outcome to specific therapies. With the identification of new mutated genes in AML since the publication of the study by Schlenk et al. [22] as well as the ability to profile the epigenetic state of AML samples, it will be intriguing to repeat such correlative efforts. In particular, it will be especially useful to use this biological information to ascertain the benefit of response to allogeneic HSCT for those under the age of 60 and the likelihood of achieving CR for the elderly with AML.

**Abbreviations**

AML, acute myeloid leukemia; CR, complete remission; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; ITD, internal tandem duplication; OS, overall survival; PCR, polymerase chain reaction.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgments**

RLL is a recipient of an Early Career Award from the Howard Hughes Medical Institute, a Clinical Scientist Development Award from the Doris Duke Charitable Foundation, and is the Geoffrey Beene Junior Chair at Memorial Sloan-Kettering Cancer Center. RLL is also supported by the National Institutes of Health (grant HL082677).
References

1. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Maligne S, Yao J, Kilipavara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL: Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-7.

2. Abdel-Wahab O, Manshour I, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Versvloet S: Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010, 70:447-52.

3. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberge P, de Witte T, van der Reijden BA, Jansen HJ: Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-42.

4. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Dissen P, Soulier J, Vigué F, Fontenay M, Vainchenker W, Bernard OA: Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2299-301.

5. Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaïde J, Olschwang S, Xerri L, Vey N, Chaffanet M, Birnbaum D, Mazzoncacci MJ: Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010, 24:649-73.

6. Mardis ER, Biegel JA, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Cristino JD, Levine RL, Versvloet S: Next-generation sequencing reveals significantly higher mutation rates in DNA from cancer patients than from normal tissue. Proc Natl Acad Sci USA 2009, 106:15040-5.

7. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL: Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-7.

8. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Burnett A: Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006, 91:1513-22.

9. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond B, Vellenga E, van Marwijk Kooym M, Verstovsek S, Verwoerd G, Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG): Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-48.

10. Bishop JP, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H, Ma D, Dodds A, Herrmann R, Szer J, Wolf MM, Young G: Etoposide in acute nonlymphocytic leukemia. Australian Leukaemia Study Group. Blood 1990, 75:27-32.

11. Estey EH, Thall PF, Cortes JE, Giles FJ, O’Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M: Comparison of idarubicin + ara-C, fludarabine + ara-C, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001, 98:3575-83.

12. Fernandez HF, Sun Z, Yao X, Lizow MR, Luger SM, Paietta EM, Racekis J, Dellow GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS: Anthracrycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361:249-59.

13. Döhner H, Witte T, Mertelsmann R, Lubbert M: Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006, 91:1513-22.

14. Burnet AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-24.

15. Karp JE, Lesczene J: Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics 2008, 2:491-500.

16. Sivers EL, Larson RA, Stadtmann EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR, Mylotarg Study Group: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244-54.

17. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germain U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-9.

18. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabalek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Lowenberg B, Delwel R, Melnick A: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.

19. Lowenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 1999, 341:1051-62.
21. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA* 2009, 301:2349-61.

22. Schlenk RF, Döhner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Häbendank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med* 2008, 358:1909-18.